Notice of Special Interest (NOSI): NIAID Administrative Supplement to Promote Discovery of Medical Countermeasures Against Chemical Threats

The NIAID is inviting administrative supplement applications from current NIAID awardees that are not currently focused on the research and early development of medical countermeasures (MCMs) against chemical threats to allow them to expand their MCM research focus into this critical field. There must be sufficient progress on the parent project to justify the additional supplemental work. The proposed supplemental activities must be within the scope of the approved aims of the parent award.

 

Scope of Interest

The Chemical Countermeasures Research Program (CCRP) was established in 2006 by the NIAID to promote the discovery and advancements of MCMs to treat and/or prevent serious morbidities and mortality during or after mass casualty, high consequence, public health events involving the release of highly toxic chemicals. In support of these goals, the CCRP seeks to promote basic research to identify mechanisms of toxic effects and application of the fundamental knowledge gained to support the discovery and early-stage development of MCMs. To learn more, see The National Institutes of Health Chemical Countermeasures Research Program (NIH CCRP): A Collaborative Opportunity to Develop Effective and Accessible Chemical Medical Countermeasures for the American People, published in Drug Development Research.

The research scope of the CCRP is the discovery and efficacy validation of post-exposure MCMs and includes: 1) Treating the acute and chronic health effects of chemical threats; 2) Easy administration in a mass-casualty situation; and 3) Rapidly effective as delayed therapies (treatment window typically ≥ 30 minutes after exposure). For this Notice of Special Interest, the post-exposure treatment window may be reduced to obtain initial proof-of-principle pilot efficacy data for use as preliminary results in subsequent CCRP application submissions for more extensive grant support where utility within a civilian-based mass casualty therapeutic window may then be explored.

Injuries caused by acute exposure to chemicals often manifest similarly or identical to conditions observed in clinical practice such as acute lung injury, acute respiratory distress syndrome, coagulopathy, tissue fibrosis, keratopathy, neovascularization, seizure, neurodegeneration, and respiratory depression, so proposals that contemplate expansion of indications of already approved/authorized therapeutics and/or those still in the exploratory or validation stage for illness, infection, disease, radiation, etc. related physiopathology are highly encouraged.

Application Due Date(s) – 3 April 2022; 1 March 2023; 1 March 2024, by 5:00 PM local time of applicant organization.

NOT-AI-22-030